Therapeutic nuclear medicine: Theranostic radiopharmaceuticals for metastatic cancer -focusing on targeted alpha therapy (Co-lead, South-Eastern Norway Regional Health Authority Grant), SIMPLERAD (Co-lead WP4, funded by the European Union), Biodistribution and dosimetry in a phase 1 trial of 224-Ra-CaCO3 particles (funded by sponsor), Dose-effects for a novel 177-Lu based treatment of non-Hodgkin lymphoma (South-Eastern Norway Regional Health Authority Research Grant), Simulation tools and quantitative 90-Y PET/CT for Selective Internal Radiation Therapy (South-Eastern Norway Regional Health Authority Innovation Grant), Dosimetry-based treatment planning of 131-I therapy.
Other studies: Quantitative PET parameters as predictors for patient outcome (part of different lymphoma trials), radiomics investigations, novel PET tracers for multiple myeloma assessments, and various technical projects related to image reconstruction and analyses.
Hindorf C, Jessen L, Kapidzic SC, Blakkisrud J, Dalmo J, Engelsen O, Gustafsson J, Sandström M, Sæterstøl J, Gleisner KS(2023) Traceable calibration with 177Lu and comparison of activity meters at hospitals in Norway and Sweden Phys Med, 116, 103170(in press) DOI 10.1016/j.ejmp.2023.103170, PubMed 37989044
Sjögreen-Gleisner K, Flux G, Bacher K, Chiesa C, de Nijs R, Kagadis GC, Lima T, Georgosopoulou ML, Gabiña PM, Nekolla S, Peters S, Santos J, Sattler B, Stokke C, Tran-Gia J, Gilligan P, Bardiès M(2023) EFOMP policy statement NO. 19: Dosimetry in nuclear medicine therapy - Molecular radiotherapy Phys Med, 103166(in press) DOI 10.1016/j.ejmp.2023.103166, PubMed 37926641
Lysvik EK, Mikalsen LTG, Rootwelt-Revheim ME, Emblem KE, Hjørnevik T(2023) Optimization of Q.Clear reconstruction for dynamic 18F PET imaging EJNMMI Phys, 10(1), 65 DOI 10.1186/s40658-023-00584-1, PubMed 37861929
Get in touch
Contact information Group Leader Caroline Stokke, PhD, Assoc. Prof., Department of Physics and Computational Radiology, carsto@ous-hf.no, (0047) 98685214